Femasys Inc. (FEMY) - Q3 2024 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended September 30, 2024. Femasys Inc. is a biomedical company focused on women's reproductive health, offering FDA-cleared products for infertility (FemaSeed, FemVue) and developing a permanent birth control solution (FemBloc). The company operates as a single segment and is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.
Key Financial Metrics
| Metric | Q3 2024 (3 Months) | Q3 2023 (3 Months) | YTD 2024 (9 Months) | YTD 2023 (9 Months) |
|---|---|---|---|---|
| Sales | $554,908 | $244,361 | $1,047,532 | $858,859 |
| Net Loss | $(5,408,860) | $(3,996,905) | $(13,692,944) | $(9,836,670) |
| Loss Per Share (Basic/Diluted) | $(0.24) | $(0.26) | $(0.62) | $(0.74) |
| Cash and Equivalents (Sep 30, 2024) | $7,611,210 | |||
| Convertible Notes Payable (Net) | $5,068,556 | |||
| Accumulated Deficit | $(122,074,573) |
Material Changes vs. Prior Period
- Revenue Growth: Sales increased 127.1% in Q3 2024 compared to Q3 2023, driven by the commercial launch of FemaSeed and increased international sales of FemVue. YTD sales grew 22.0%.
- Operating Expenses: Sales and marketing expenses surged 2,118% in Q3 2024 due to the recruitment of a commercial team for FemaSeed. R&D expenses increased 11.1% primarily due to higher compensation and consultant costs.
- Interest Expense: Interest expense increased significantly (5,044% in Q3) due to the amortization of debt discounts and issuance costs related to the $6.85 million convertible notes issued in November 2023.
- Liquidity: Cash and cash equivalents decreased from $21.7 million at year-end 2023 to $7.6 million at September 30, 2024, reflecting a net cash burn of $14.1 million over the nine-month period.
Guidance, Outlook, and Risks
- Going Concern: The company has disclosed substantial doubt about its ability to continue as a going concern. Management estimates current cash resources are sufficient only through July 2025, necessitating additional financing to fund operations and the FemBloc clinical trial.
- Commercial Progress: Femasys announced strategic distribution partnerships in Spain for FemaSeed and FemVue, with orders totaling over $1.3 million expected over the next year. The company also secured a partnership with Boston IVF.
- Clinical Development: The pivotal FINALE trial for FemBloc (permanent birth control) is actively enrolling at six sites. An interim analysis is planned once 300 women have used the device for one year.
- Regulatory Milestones: The company received FDA 510(k) clearance for FemChec (diagnostic) and CE Mark certification for multiple products in 2024.
- Risks: Key risks include the inability to secure additional financing, delays in regulatory approvals for FemBloc, and the volatility of the common stock price.
Investor Verification Checklist
- Cash Runway: Verify the timeline for the next financing round given the "substantial doubt" disclosure and cash burn rate of ~$4.5 million per quarter.
- Convertible Note Terms: Review the conversion price ($1.18) and redemption triggers for the $6.85 million notes maturing in November 2025.
- Revenue Recognition: Confirm the timing of revenue recognition for the Spanish distributor orders, noting that one order was delayed by Hurricane Helene and recognized in October 2024.
- FemBloc Trial Enrollment: Monitor the pace of enrollment in the pivotal FINALE trial to assess the timeline for potential FDA approval.
- At-The-Market (ATM) Facility: Track the remaining capacity under the Equity Distribution Agreement with Piper Sandler, noting $900k in proceeds were raised in October 2024.